0
Catégories
Documents disponibles dans cette catégorie (30)
Ajouter le résultat dans votre panier Affiner la recherche
Titre : Addressing challenges in adolescent smoking cessation : design and baseline characteristics of the HS Group-Randomized trial Type de document : texte imprimé Auteurs : Jingmin Liu, Auteur ; Jr. Peterson, Auteur ; V. Arthur, Auteur ; Kathleen A. Kealey, Auteur ; Sue L. Mann, Auteur ; Jonathan B. Bricker, Auteur ; Patrick M. Marek, Auteur Editeur : Paris [France] : Elsevier Année de publication : 2007 Collection : Preventive Medecine Note générale : Dans la bibliothèque virtuelle (articles scientifiques) Langues : Anglais (eng) Catégories : [DIVERS] personne:famille:adolescent
[DIVERS] personne:par âge:jeune
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagiqueIndex. décimale : TA 3.2.2.1 Expérimentation Résumé : Objective. Well-documented challenges have hampered both intervention development and research in teen smoking cessation. Addressing these challenges, the Hutchinson Study of High School Smoking (HS Study), the largest group-randomized trial in adolescent smoking cessation to date, incorporates several design innovations to investigate the effect of a counselor-initiated, individually tailored telephone counseling smoking cessation intervention for older adolescents. This paper presents and discusses these innovative design features, and baseline findings on the resulting study population. Method. The trial used a population-based survey to proactively identify and recruit all high school juniors who had smoked in the past month - potentially expanding intervention reach to all smokers, even those who smoked less than daily and those not motivated to quit. For ethical and intervention reasons, some nonsmokers were enrolled in the intervention, also. Other important design features included the random allocation of schools into experimental conditions (intervention vs. no-intervention control) and a multi-wave design. Results and conclusion. The design innovations address problems and challenges identified in adolescent smoking cessation literature. The heterogeneous baseline characteristics of the study population, well-balanced between the two arms, have three significant implications: They (1) demonstrate the effectiveness of the trial's design features, (2) highlight Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2696 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002091 TA 3.2.2.1 LIU A Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST) / R. Cambell (10/05/2008)
Titre : An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST) : a cluster randomised trial Type de document : texte imprimé Auteurs : R. Cambell, Auteur ; F. Starkey, Auteur ; J. Holliday, Auteur Editeur : Lancet Année de publication : 10/05/2008 Collection : The Lancet num. 371 (9624) Importance : p.1595-1602 Note générale : deux exemplaires Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] législation:milieu réglementé:milieu scolaire:école secondaire
[TABAC] prévention
[TABAC] sevrage tabagique:aide au sevrageIndex. décimale : TA 5.3.1 Programmes scolaire de prévention Résumé : Dans de nombreux pays, les écoles s'embarquent dans des programmesde prévention du tabagisme, mais les revues systématiques ont montré une preuve composite de leur efficacité. La plupart des approches menées par les pairs a été mis en place dans les classes, et les évaluations rigoureuses sont rares. L'étude présentée dans ce document montre l'efficacité d'une intervention menée par les pairs qui avait pour but de prévenir la consommation de tabagisme dans les écoles secondaires. En ligne : https://www.sciencedirect.com/science/article/pii/S0140673608606923 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2770 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 002009 TA 5.3.1 CAM I Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Clinical study protocol on electronic cigarettes and nicotine pouches for smoking cessation in Pakistan / Abdul Hameed (2024)
Titre : Clinical study protocol on electronic cigarettes and nicotine pouches for smoking cessation in Pakistan : a randomized controlled trial Type de document : document électronique Auteurs : Abdul Hameed, Auteur ; Daud Malik, Auteur Editeur : Springer Année de publication : 2024 Collection : Trials, ISSN 1745-6215 num. 25:9 Importance : 15 p. Présentation : ill, tab. Langues : Anglais (eng) Catégories : [DIVERS] géographie:Asie:Proche et Moyen-Orient:Pakistan
[DIVERS] géographie:pays en développement
[TABAC] CANDIDATS:e-cigarette
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagiqueMots-clés : pouche Index. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Background
Pakistan is one of most vulnerable low- and middle-income countries with 29 million adult active tobacco users. Smoking cessation services are lacking as the tobacco control initiatives have largely failed to address the smoking endemic. Over the last 5 years, Pakistan has witnessed the use of innovative tobacco harm reduction (THR) products such as e-cigarettes and nicotine pouches. However, their use remains limited. THR products are imported legally as consumer goods and are taxable. The lack of sufficient data for THR and its application is a challenge
in gauging their effectiveness in assisting smokers quit combustible smoking. Evidence-based studies can help in measuring the effectiveness of e-cigarettes and nicotine pouches as smoking cessation aids.
Method
Keeping in view the study objectives, a sample size of 600 participants will be sufficient to assess the effectiveness of e-cigarettes and nicotine pouches for smoking cessation in Pakistan. Of these, 200 participants each will receive e-cigarettes and nicotine pouches along with basic care counselling, while the remaining 200 participants will only receive basic care counselling for 48 weeks. The association of participants’ characteristics with smoking and health status will be based on the bivariate and multivariate analysis. The simple t-test and variance analysis will
assess the differences in intervention indicators between the control and treatment groups. For the inferential analysis, the average treatment impact will be based on the quasi-experimental techniques such as difference in difference (DID) or propensity score matching (PMS).
Discussion
The study will evaluate the participants at the baseline as they decide the quit date. After every 12 weeks, a follow-up survey with the participants will be conducted. Results are anticipated to inform the public, decisionmakers, and researchers about the effects of using e-cigarettes and nicotine pouches in the short- and medium-term periods. Critically, the potential of e-cigarettes and other alternative nicotine delivery systems as smoking cessation aid will be assessed.
En ligne : https://doi.org/10.1186/s13063-023-07876-y Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10228 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : A comparison of sustained-release bupropion and placebo for smoking cessation Type de document : texte imprimé Auteurs : Richard D. Hurt, Auteur ; David P.L. Sachs, Auteur ; Elbert T. Glover, Auteur ; Kenneth P. Offord, Auteur Editeur : Massachusetts Medical Society Année de publication : 1997 Collection : New England Journal of Medicine num. 337:17 Importance : p. 1195-1202 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:placeboIndex. décimale : TA 6.2.3.2 Autres produits Résumé : BACKGROUND AND METHODS:
Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or "target quit date") was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less.
RESULTS:
At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P=0.02) and the 300-mg group (P=0.01) -- but not the 100-mg group (P=0.09) -- were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P= 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups.
CONCLUSIONS:
A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year.En ligne : https://www.nejm.org/doi/10.1056/NEJM199710233371703?url_ver=Z39.88-2003&rfr_id= [...] Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8138 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler Type de document : document électronique Auteurs : Robert West, Auteur ; Peter Hajek, Auteur ; J. Foulds, Auteur ; Fredrik Nilsson, Auteur ; Sylvia May, Auteur ; Anna Meadows, Auteur Editeur : Springer Année de publication : 2000 Collection : Psychopharmacology num. 149(3) Importance : p.198-202 Langues : Anglais (eng) Catégories : [TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:chewing-gum
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:inhalateur
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotine
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:spray nasal
[TABAC] tabagisme:dépendance tabagique:dépendance psychologique
[TABAC] tabagisme:évaluation du tabagisme:test de dépendance à la nicotineIndex. décimale : TA 6.2.3.1 Substitution nicotinique Résumé : Rationale: Nicotine replacement therapy (NRT) in varying forms is becoming widely used. Clinicians, therapists and regulatory authorities are interested in the abuse liability and dependence potential of the different forms.
Objectives: To compare the abuse liability and dependence potential of nicotine gum, transdermal patch, spray and inhaler.
Methods: 504 male and female smokers seeking help with stopping smoking were randomly allocated to the four products. Measures were taken at the designated quit date, then 1 week, 4 weeks, 12 weeks and 15 weeks later. Smokers were advised to use the product for up to 12 weeks. Those still using the product at the 12-week visit were advised to cease use by week 14. Measures included: pleasantness and satisfaction ratings at weeks 1 and 4 (used as a marker of abuse liability); ratings of feeling dependent on NRT at weeks 1, 4, 12 and 15 (used as a marker of subjective dependence); mood and physical symptoms ratings at weeks 12 and 15 (the change being used to assess physical dependence on NRT), continued usage of NRT at week 15 (used as an marker of behavioural dependence).
Results: Average ratings of pleasantness were low. The nicotine patch was rated as less unpleasant to use than all other products. There were no significant differences between the products in terms of satisfaction or subjective dependence except at week 15 when no patch users rated themselves as dependent. Continued use of NRT at week 15 was related to rate of delivery of nicotine from the products - 2% for patch, 7% for gum and inhaler, 10% for spray (P<0.05 for linear association). Among those
En ligne : https://doi.org/10.1007/s002130000382 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10350 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice Type de document : texte imprimé Auteurs : J.A. Stapleton, Auteur ; M.A.H. Russel, Auteur ; C. Feyerabend, Auteur ; S.M. Wiseman, Auteur ; G. Gustavsson, Auteur ; U. Sawe, Auteur ; D. Wiseman, Auteur Editeur : Society for the study of addiction to alcohol and other drugs Année de publication : 1995 Collection : Addiction num. 90 Importance : p. 31-42 Catégories : [TABAC] étude:recherche:recherche clinique
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique
[TABAC] sevrage tabagique:aide au sevrage
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:patch à la nicotine
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] tabagisme
[TABAC] tabagisme:effet du tabacIndex. décimale : TA 6.2.3.1.2 Transcutané Résumé : Le patch à la nicotine est reconnu comme une aide efficace dans le sevrage tabagique. La facilité et la sécurité du traitement lui donne un avantageux potentiel sur le chewing-gum nicotinique comme adjoint dans les soins primaires que l'on peut mettre en place dans le domaine de la santé publique. Cette étude tente de le démontrer à l'aide d'une enquête basée sur des expériences pratiques. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=1408 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 000164 TA 6.2.3.1.2 STA D Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effect of maintenance therapy withvarenicline on smoking cessation : a randomized controlled trial Type de document : texte imprimé Auteurs : Serena Tonstad, Auteur ; Philip Tonnesen, Auteur ; Peter Hajek, Auteur Editeur : American Medical Association (AMA) Année de publication : 01/06/2006 Collection : JAMA : Journal of the American Medical Association num. 296 (1) Importance : p.64-71 Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2590 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001434 TA 6.2.3.1.4 TON E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effect of patient navigation and financial incentives on smoking cessation among primary care patients at an urban safety-net hospital Type de document : document électronique Auteurs : Karen E. Lasser, Auteur ; Lisa M. Quintiliani, Auteur ; Ve Truong, Auteur Editeur : American Medical Association (AMA) Année de publication : 2017 Collection : JAMA Internal Medicine num. 177(12) Importance : p. 1798–1807 Langues : Anglais (eng) Catégories : [TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] législation:milieu réglementé:hôpital
[TABAC] sevrage tabagique
[TABAC] tabagisme:aspect économiqueIndex. décimale : TA 2.2 Pays industrialisés Résumé : In this study of adult daily smokers at 1 large urban safety-net hospital, patient navigation and financial incentives for smoking cessation significantly increased the rates of smoking cessation. En ligne : https://doi.org/10.1001%2Fjamainternmed.2017.4372 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=9908 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effect of smoking cessation counseling on recovery from alcoholism : findings from a randomized community intervention trial Type de document : texte imprimé Auteurs : J.K. Bobo, Auteur ; H.E. Mcllvain, Auteur ; H.A. Lando, Auteur ; R.D. Walker, Auteur ; A. Leed-Kelly, Auteur Editeur : Society for the study of addiction to alcohol and other drugs Année de publication : 1998 Collection : Addiction num. 93 (6) Importance : p. 877-887 Note générale : biblio. Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique
[TABAC] tabagisme
[TABAC] tabagisme:risque:facteur associé:alcoolIndex. décimale : TA 0.1.1 Congrès, conférence et colloque Résumé : L'article évoque les effets du sevrage tabagique sur le sevrage d'alcool, en étudiant un groupe de participant. Ce n'est pas concluant. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=1409 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 000485 TA 0.1.1 SMO S Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effect on smoking quit rate of telling patients their lung age : the Step2quit randomised controlled trial Type de document : texte imprimé Auteurs : Gary Parkes, Auteur ; Trisha Greenlaugh, Auteur ; Mark Griffin, Auteur ; Richard Dent, Auteur Editeur : BMJ Publishing Group Année de publication : 06/03/2008 Collection : British Medical Journal num. online Importance : 7 p. Catégories : [DIVERS] anatomie:corps humain:appareil respiratoire:poumon
[DIVERS] personne:patient
[TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagiqueIndex. décimale : TA 6.7 Facteurs influents (grossesse, adolescence…) Résumé : L'objectif de cette étude est d'évaluer l'impact de l'âge pulmonaire estimé par la spirométrie sur les patients en tant qu'incitant à arrêter de fumer. En ligne : https://www.bmj.com/content/336/7644/598 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=1490 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Effectiveness of nicotine salt vapes, cytisine, and a combination of these products, for smoking cessation in New Zealand : protocol for a three‑arm, pragmatic, community‑based randomised controlled trial Type de document : document électronique Auteurs : Natalie Walker, Auteur ; Amanda Calder, Auteur ; Joanne Barnes, Auteur Editeur : BioMed Central Année de publication : 2023 Collection : BMC Public Health Importance : 11 p. Présentation : ill., tab. Langues : Anglais (eng) Catégories : [TABAC] CANDIDATS:e-cigarette
[TABAC] chimie du tabac:constituant:alcaloïde:nicotine
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[DIVERS] géographie:Océanie:Nouvelle-ZélandeIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Background
Combining short-acting nicotine replacement therapy with varenicline increases smoking cessation rates compared with varenicline alone, but not all people tolerate these medications or find them helpful. We aim to investigate the therapeutic potential of an analogous combination, by evaluating the effectiveness, safety, and acceptability of combining nicotine salt e-cigarettes with cytisine, compared to nicotine salt e-cigarettes or cytisine only, on smoking abstinence at six months.
Methods
A pragmatic, community-based, investigator-blinded, randomised superiority trial design will be utilised. Eligible participants will be people who smoke daily (N = 800, 90% power) from throughout New Zealand, who are: aged ≥ 18 years, motivated to quit in the next two weeks, able to provide online consent, willing to use e-cigarettes and/or cytisine, and have daily access to a mobile phone. Recruitment will utilise multi-media advertising. Participants will be randomised (3:3:2 ratio) to 12 weeks of: 1) e-cigarettes (closed pod system, 3% nicotine salt, tobacco flavour)
plus cytisine; 2) e-cigarettes alone, or 3) cytisine alone. All groups will receive a six-month, text-message-based behavioural support programme. The primary outcome is self-reported, biochemically verified, continuous abstinence at six months post-quit date. Secondary outcomes, measured at quit date, then one, three, six, and 12 months post-quit date, include self-reported continuous abstinence, 7-day point prevalence abstinence, cigarettes smoked per day, withdrawal and urge to smoke, time to (re)lapse, treatment use and compliance, treatment crossover, dual-use, use of other cessation products, change in e-cigarette products, continuation of product use, acceptability, change in health state, health-related quality of life, change in body mass index, adverse events, and cost per quitter.
Discussion
Pragmatic trials are of particular value as they reflect the ‘real world’ impact of interventions. The trial will provide some of the first evidence on the effectiveness of combining nicotine salt e-cigarettes with cytisine for smoking cessation, in a country with strong tobacco control policy. Findings will be incorporated into relevant systematic reviews, informing practice and policy.En ligne : https://doi.org/10.1186/s12889-023-16665-w Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10264 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease : a randomized trial Type de document : texte imprimé Auteurs : Nancy A. Rigotti, Auteur ; Andrew L. Pipe, Auteur ; Neal L. Benowitz, Auteur ; Carmen Arteaga, Auteur Editeur : Lippincott Williams & Wilkins Année de publication : 2010 Collection : Circulation, ISSN 0009-7322 num. 121:2 Importance : p. 221-229 Langues : Anglais (eng) Catégories : [TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:pathologie:pathologie cardio-vasculaireIndex. décimale : TA 6.2.3.2 Autres produits Résumé : BACKGROUND:
Smoking cessation is a key component of secondary cardiovascular disease prevention. Varenicline, a partial alpha4beta2 nicotinic acetylcholine receptor agonist, is effective for smoking cessation in healthy smokers, but its efficacy and safety in smokers with cardiovascular disease are unknown.
METHODS AND RESULTS:
A multicenter, randomized, double-blind, placebo-controlled trial compared the efficacy and safety of varenicline with placebo for smoking cessation in 714 smokers with stable cardiovascular disease. Participants received varenicline (1 mg twice daily) or placebo, along with smoking-cessation counseling, for 12 weeks. Follow-up lasted 52 weeks. The primary end point was carbon monoxide-confirmed continuous abstinence rate for weeks 9 through 12 (last 4 weeks of treatment). The continuous abstinence rate was higher for varenicline than placebo during weeks 9 through 12 (47.0% versus 13.9%; odds ratio, 6.11; 95% confidence interval [CI], 4.18 to 8.93) and weeks 9 through 52 (19.2% versus 7.2%; odds ratio, 3.14; 95% CI, 1.93 to 5.11). The varenicline and placebo groups did not differ significantly in cardiovascular mortality (0.3% versus 0.6%; difference, -0.3%; 95% CI, -1.3 to 0.7), all-cause mortality (0.6% versus 1.4%; difference, -0.8%; 95% CI, -2.3 to 0.6), cardiovascular events (7.1% versus 5.7%; difference, 1.4%; 95% CI, -2.3 to 5.0), or serious adverse events (6.5% and 6.0%; difference, 0.5%; 95% CI, -3.1 to 4.1). As a result of adverse events, 9.6% of varenicline and 4.3% of placebo participants discontinued study drug.
CONCLUSIONS:
Varenicline is effective for smoking cessation in smokers with cardiovascular disease. It was well tolerated and did not increase cardiovascular events or mortality; however, trial size and duration limit definitive conclusions about safety.En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4096941/ Format de la ressource électronique : PDF, HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8369 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001432 TA 6.2.3.1.4 JOR E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute : a prospective 12-month randomized control design study Type de document : texte imprimé Auteurs : Pasquale Caponnetto, Auteur ; Davide Campagna, Auteur ; Fabio Cibella, Auteur ; Jaymin B. Morjaria, Auteur ; Massimo Caruso, Auteur ; Cristina Russo, Auteur ; Riccardo Polosa, Auteur Editeur : Public Library of Science (PLOS) Année de publication : 2013 Collection : PLOS Medicine num. 8(6) Importance : http://dx.doi.org/10.1371/journal.pone.0066317 Présentation : ill. Langues : Français (fre) Catégories : [TABAC] chimie du tabac:tabac fumé:cigarette:cigarette électronique
[TABAC] étude:recherche:recherche clinique:essai clinique randomiséIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Methods ECLAT is a prospective 12-month randomized, controlled trial that evaluates smoking reduction/abstinence in 300 smokers not intending to quit experimenting two different nicotine strengths of a popular e-cigarette model (‘Categoria’; Arbi Group Srl, Italy) compared to its non-nicotine choice. GroupA (n = 100) received 7.2 mg nicotine cartridges for 12 weeks; GroupB (n = 100), a 6-week 7.2 mg nicotine cartridges followed by a further 6-week 5.4 mg nicotine cartridges; GroupC (n = 100) received no-nicotine cartridges for 12 weeks. The study consisted of nine visits during which cig/day use and exhaled carbon monoxide (eCO) levels were measured. Smoking reduction and abstinence rates were calculated. Adverse events and product preferences were also reviewed. En ligne : http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066317 Format de la ressource électronique : HTML, PDF Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7990 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Electronic cigarette vaping with nicotine causes Increased thrombogenicity and impaired microvascular function in healthy volunteers : a randomised clinical trial Type de document : document électronique Auteurs : Gustaf Lyytinen, Auteur ; Amelie Brynedal, Auteur ; Erik Anesäter, Auteur Editeur : Springer Science Business Media Année de publication : 2023 Collection : Cardiovascular Toxicology Importance : pp. 255-264 Présentation : graph., tab. Langues : Anglais (eng) Catégories : [TABAC] CANDIDATS:e-cigarette
[TABAC] chimie du tabac:constituant:alcaloïde:nicotine
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] tabagisme:pathologie:pathologie cardio-vasculaire:accident vasculaireIndex. décimale : TA 1.1.1 Cigarettes (« normales », électroniques, aromatisées,…) Résumé : Electronic cigarette (EC) vaping is increasingly popular, despite growing evidence of adverse health effects. To further evaluate the impact of EC use on vascular health, we investigated the effects of brief EC inhalation on flow-dependent thrombus formation and microcirculation in healthy volunteers. The study was performed with a randomised double-blind crossover design. Twenty-two healthy subjects aged between 18 and 45 years with occasional tobacco use were recruited. Subjects inhaled 30 puffs of EC aerosol with and without nicotine on two occasions separated by a wash-out period of at least 1 week. Blood samples were collected at baseline and at 15 and 60 min following exposure and analysed with the Total-Thrombus-formation analysis system evaluating fibrin-rich thrombus formation and platelet thrombus formation in whole blood under flow. Microvascular function was assessed at baseline and 30 min after exposure by laser speckle contrast
imaging and iontophoresis of acetylcholine and sodium nitroprusside (SNP) to evaluate the endothelium-dependent and independent pathways of vasodilation. Compared with nicotine free EC aerosol, exposure to EC aerosol with nicotine significantly increased platelet thrombus formation and fibrin-rich thrombus formation at 15 min (p = 0.017 and p = 0.037, respectively) with normalisation after 60 min. Peak SNP-mediated microvascular perfusion, i.e. endothelium-independent vasodilation, was reduced following EC vaping with nicotine compared with baseline (p = 0.006). Thirty puffs of EC aerosol with nicotine increased platelet and fibrin-dependent thrombus formation and reduced microvascular dilatation capacity. No compelling effects of EC vaping without nicotine were observed, indicating nicotine as the main effector.
En ligne : https://doi.org/10.1007/s12012-023-09802-9 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10265 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
